Our focus on the patient drives everything we do and as a result, our path forward is clear: to develop game-changing cell and gene therapies for localized treatment of the underlying cause of debilitating diseases.
— David Pernock, Chairman and Chief Executive Officer
Applying the unique characteristics of autologous fibroblasts to cell and gene therapies
azficel-T offers the potential to address the underlying cause of chronic dysphonia by using the patient’s own cells for localized treatment of the lamina propria layer of the scarred vocal folds.
FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of functional Type VII collagen locally to the affected areas.
FCX-013 offers the potential to address the underlying cause of linear scleroderma by regulating collagen accumulation at the site of the localized disease.
Photo middle left: Courtesy of debra–The Dystrophic Epidermolysis Bullosa Research Association of America. Used with permission.